DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer

Hetakshi Kurani(University of Miami), Joyce M. Slingerland(Georgetown University)
Clinical Cancer Research
February 7, 2022
10.1158/1078-0432.ccr-21-1299
Cited by 71

Related Papers

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
|Journal of Clinical Investigation|2011|417
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis
|Cell Reports|2022|32